Enhanced recovery after surgery (ERAS) is an established pathway to improve short-term outcomes in colorectal surgery. It is unclear whether the efficacy, feasibility, and safety of the ERAS protocol are similar in older and younger patients.The study examined adherence to the ERAS protocol and identified factors leading to deviations in older patients.
Lee et al. show that neutrophil extracellular traps (NETs) establish the pre-metastatic niche in the omentum by recruiting innate-like B cells and eliciting IL-10 production in…
Explore the 2024 CPT codes for oncology patient navigation and how pharma can support improved patient outcomes.
Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care
Retrospective data showed there was no OS difference between 3 frontline CDK4/6 inhibitor combos in HR-positive breast cancer.
Pancreatic cancer is a tough disease to catch early because it doesn’t always cause clear symptoms right away. Still, noticing changes in your body can…
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they…
Stacey A. Cohen, MD, discusses insights into the evolving role of circulating tumor DNA in clinical decision-making for patients with colorectal cancer.
The FDA accepted and granted priority review to an NDA for avutometinib plus defactinib in recurrent KRAS-mutated low-grade serous ovarian cancer.
Maurice Pérol, MD, presents a pooled analysis of two pivotal Phase 2 trials assessing the efficacy and safety of taletrectinib in patients with advanced ROS1+…
These long-term results support METex14 as a targetable oncogenic driver in NSCLC and add to the evidence supporting capmatinib as a targeted treatment option for…
